Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Formulation of Sustained Release Matrix Tablets Containing Ibudilast with Hydroxypropylmethylcellulose Phthalate and Ethylcellulose

히드록시프로필메칠셀룰로오스 프탈레이트 및 에칠셀룰로오스를 이용한 이부딜라스트 함유 서방성 매트릭스 정제의 개발

  • Published : 2007.12.21
Download PDF
⟨ Previous Next ⟩

Abstract

To develop a sustained-release tablet which had the similar dissolution to commercial ibudilast-loaded sustained-release capsule, the tablets were prepared using hydroxypropylmethylcellulose phthalate (HPMCP), ethylcellulose (EC) and hydroxypropylcellulose (HPC), and dissolution test were carried out with paddle method in KP. The tablet prepared only with HPMCP and EC showed sno similar dissolution pattern to the commercial product. As the ratio of HPMCP/HPC in tablet decreased, the dissolution rate of drug decreased in pH 1.2 but increased in pH 6.8. Furthermore, an ibudilast-loaded sustained-release tablet composed of [ibudilast/EC/HPMCP/HPC (10/10/170/10 mg/tab)] gave similar dissolution to commercial product in pH 1.2 for 3 h and in pH 6.8 for 10 h. Thus, it could be a potential candidate for the substitute of commercial capsule.

Keywords

References

  1. Y. Kishi, S. Ohta, N. Kasuya, T. Ashikaga and M. Isobe, Ibudilast, A Non-selective PDE Inhibitor with Multiple Actions on Blood Cells and Vascular Wall, Cardiovasc. Drug Rev., 19(3), 215-225 (2001) https://doi.org/10.1111/j.1527-3466.2001.tb00066.x
  2. L. C. D. Gibson, S. F. Hastings, I. McPhee, R. Rhee, A. Clatyon, C. E. Darroch, A. Mackenzie, P. A. Stevens and S. J. Mackenzie, The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family, Eur. J. Pharmacol., 538, 39-42 (2006) https://doi.org/10.1016/j.ejphar.2006.02.053
  3. J. Feng, T. Misu, K. Fujihara, S. Sakoda, Y. Nakatsuji, H. Fukaura, S. Kikuchi, K. Tashiro, A. Suzumura, N. Ishii, K. Sugamura, I. Nakashima and Y. Itoyama, Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Thl/Th2 balance and NKT cell subset in multiple sclerosis, Mult. Scler., 10, 494-498 (2004) https://doi.org/10.1191/1352458504ms1070oa
  4. T. Mizuno, T. Kurotani, Y. Komatsu, J. Kawanokuchi, H. Kato, N. Mitsuma and A. Suzumura, Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia, Neuropharmacology, 46, 404-411 (2004) https://doi.org/10.1016/j.neuropharm.2003.09.009
  5. M. Niwa, K. Kohno, L. Y. al Essa, M. Kobayashi, M. Nozaki and K. Tsurumi, Ibudilast, an anti-allergic and cerebral vasodilator, modulates superoxide production in human neutrophils, Life Sciences., 56, 107-115 (1995) https://doi.org/10.1016/0024-3205(94)00420-W
  6. W. M. Armstead, R. Mirro, C. W. Leffler and D. W. Busija, The role of prostanoids in the mediation of responses to KC-404, a novel cerebrovasodilator, J. Pharmacol. Exp. Ther., 244, 138-143 (1988)
  7. A. Kawasaki, K. Hoshino, R. Osaki, Y. Mizushima and S. Yano, Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma, J. Asthma., 29, 245-252 (1992) https://doi.org/10.3109/02770909209048938
  8. S. Yokogaki, Y. Suzuki and M. Ohashi, Introduction of a new anti-allergic ophthalmic solution: ibudilast ophtalmic solution (Ketas Eye drops), Jpn. J. Ocul. Pharmacol., 16, 24-28 (2002)
  9. K. Noguchi, K. Kobayashi, M. Nishikibe and F. Ikemeto, Preventive effect of ophthalmic ibudilast on experimental allergic conjunctivitis in the guinea pig, Journal of Eye., 11, 1747-1754 (1994)
  10. YANG Yi-Mei, CHEN Shu-Juan, Gu Shi-Fen, ZHANG Bin, DAI Zong-Shun and ZENG Fan-Dian, Pharmacokinetics and relative bioavailability of domestic ibudilast sustained release capsules in healthy volunteers, Chin J. Clin Pharmacol Ther., 5(4), 330-332 (2000)
  11. J. J. Torrado and L. L. Augsburger, Effect of different excipients on the tab1eting of coated particles, Int. J. Pharm., 106, 149-155 (1994) https://doi.org/10.1016/0378-5173(94)90313-1
  12. AR. Menjoge and MG. Kulkarni, Blends of reverse enteric polymer with Enteric and pH-independent polymers: mechanistic investigations for tailoring drug release. Bio-macromolecules., 8(1), 240-51 (2007) https://doi.org/10.1021/bm060540+
  13. Jeong Young-II, Ohno Tomoya, Hu Zhaopeng, Yoshikawa Yukako, Nobuhito Shibata, Nagata Shunji and Takada Kanji, Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method, J. Control. Release., 71, 175-182 (2001) https://doi.org/10.1016/S0168-3659(01)00211-5
  14. N. Davies Peter, E. C. Harry, Worthington, Fridrun Podczeck and J. Michael Newton, The determination of the mechanical strength of tablets of different shapes, Eur. J. Pharm. Biopharm., 67, 268-276 (2007) https://doi.org/10.1016/j.ejpb.2007.01.014
  15. P. Rajniak, C. Mancinelli, R. T. Chern, F. Stepanek, L. Farber and B.T., Hill Experimental study of wet granulation in fluidized bed: Impact of the binder properties on the granule morphology, Int. J. Pharm., 334, 92-102 (2007) https://doi.org/10.1016/j.ijpharm.2006.10.040